22258-Breast Cancer-NA-300

Breast Cancer

GS-US-595-6184: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/OptimICE-RD)

  • Details

ClinicalTrials.gov ID: NCT05633654
Diagnosis Type: NA
USOR Number:

  • Address


,
P:

Search by practice name, trial titles, indicators and specific disease types.